An innovative research effort has revealed that administering stem cells to fetuses diagnosed with spina bifida as part of a surgical repair can be a "major milestone" in treating birth defects.
Trial Details and Safety
The US-based trial involved six developing infants with the 'open' form of spina bifida. Doctors administered mother's placental stem cells on the exposed area of the developing neural column during the repair procedure.
Significantly, the cell therapy proved to be secure. The study team reported that the treatment did not lead to cancerous growths, hinder surgical recovery, or impede the resolution of co-occurring hindbrain herniation.
Positive Developments
Imaging conducted after delivery confirmed a complete reversal of Chiari malformation in each of the babies. This favorable anatomical change is a key indicator for better mobility and function.
"In the event it allows a greater number of infants to achieve ambulation who wouldn't have, then it would become the conventional approach," said the lead researcher. "The outcomes appear profoundly encouraging and pave the way for lots of potential innovative interventions."
Broader Impact and Encouragement
Experts not involved in the trial indicated that further confirmation of these observed advantages could signal a "new era" in in-utero treatment. The prospect of enhancing nerve function impairment present before birth is viewed as a transformative goal.
Particularly welcome would be advancements for bladder and bowel function, which are common challenges for those diagnosed with this disorder.
The Path Forward
While this initial trial was small in scale, its safety demonstration and positive signals offer a robust platform for larger, more comprehensive studies. The addition of cellular treatment with proven prenatal surgical methods holds considerable promise for transforming outcomes for infants diagnosed prenatally with spina bifida.